Cysticercosis by Taenia solium is an important disease caused by the presence of larval stage in swine and human, can produce several clinical manifestation including death. In MCxico 10% of medical attention in neurological disease is because cysticercosis. The lack of economical resources and poor hygiene in the communities, difficult the implantation of preventive methods. However molecules capable to induce protection against helminths have been proposed, for example, the Glutathione S-Transferase (GST), the Triose phosphate isomerase (TPI) and the Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). These enzymes are vaccine candidates against schistosomiosis. The aim of this study is the partial characterization of TPI and G A P D H of Taenia solium for future use in vaccination assays. cDNA clones of TPI and G A P D H isolated from a library, encodes a protein of 250 and 336 amino acids respectively. Amino acids sequences have a strong homology with others reported enzymes. The Taenia TPI had conserved catalytic site amino acids and astructure characteristic of this enxymes with 8 domains alpha-beta. The cDNAs coding to the enzymes were cloned into the expression vector pRSET to produce the recombinant enzymes. The recombinant TPI and G A P D H shown a molecular mass of 27 kDa and 35 kDa respectively determined by SDS-PAGE. The recombinant TPI has catalytic activity and preliminary vaccination assays with this enzyme promoted 55% of parasite reduction in a cysticercosis murine model.
Background: Hepatitis C virus has global burden, but it is a potentially curable disease, with sustained virologic response among the majority of treated patients. In recent years, new treatments for hepatitis C have been approved and represent a major advancement in treatment. Objectives: This study was conducted to assess knowledge, opinions and perceived barriers to hepatitis c direct-Acting Antivirals (DAAs) based regimen among a sample of hepatitis C virus (HCV) treatment providers. Methods: A Cross-sectional study on HCV treatment providers at El-Demerdash, Ain Shams University Hospital was conducted. A total of 69 physicians responded to self-administered questionnaire about their knowledge, opinions on the services provided and perception towards treatment barriers. Results: Most of physicians' opinions agreed with the current state of HCV care as exist of guidelines, patients have adequate access to HCV treatment providers; but they disagreed about that the general public is aware of HCV and know that it is a curable disease. Most of physicians (81%) had high Knowledge level of HCV treatment principles. The most perceived barriers to care were Payer-related barriers followed by government-related barriers and patient-related barriers. Conclusion: The study highlights the most perceived barriers that may impede the prompt and appropriate treatment of hepatitis C virus infection reported by treating physicians. Therefore, it is important to engage HCV treatment providers in Educational programs that can help to modify their knowledge about HCV treatment and related services, and their communication and practice in guiding patients in their treatment course.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.